List view / Grid view

Sandy Primrose (Newcells Biotech)



In vitro platforms for de-risking nephrotoxicity during drug development

25 March 2020 | By ,

If not correctly assessed, drug candidates with undesirable safety issues may progress through clinical development, resulting in costly failures later in the development process. Given that many drugs fail in clinical trials due to nephrotoxicity, this article describes the importance of understanding kidney transporter function in drug development, how current…